biostudies-literatureStrosberg JAdvanced Accelerator Applications, a Novartis CompanyNCATS NIH HHSNCI NIH HHS2372-2382https://www.ebi.ac.uk/biostudies/studies/S-EPMC7396396biostudies-literatureUnknown47(10)<h4>Purpose</h4>To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate.<h4>Methods</h4>In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.<h4>Results</h4>Significantly prolonged median PFS occurred with <sup>177</European journal of nuclear medicine and molecular imagingImpact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate: an analysis of the NETTER-1 study.PMC7396396N/AP30 CA008748P30 CA086862P50 CA174521UL1 TR001863Baum RPHobday TSeregni EBenson AMorse MReed NLebtahi RDeroose CMHendifar AMetz DCBodei LNETTER-1 study groupErion JLBaudin ESantoro PDelpassand EHe BSrirajaskanthan RCaplin MStrosberg JYao JBerlin JGrande EMittra EAl-Nahhas AKunz PLGericke GMora JGiammarile FKulke MHVerslype CTaieb DWolin EMariani MFPolack BDAnsquer CCourbon FKrenning EO'Dorisio TMOberg KRavasi LGrana CMSeveri SRuszniewski PBushnell DPavel MPaganelli GfalseImpact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate: an analysis of the NETTER-1 study.<h4>Purpose</h4>To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate.<h4>Methods</h4>In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.<h4>Results</h4>Significantly prolonged median PFS occurred with <sup>177</2020-01-01T00:00:00Z2020 Sep2026-05-02T21:38:34.749Z2020-08-17T07:11:30ZS-EPMC73963963212396910.1007/s00259-020-04709-x